Search Results
Dec 18, 2025, 08:00 ET IDrive Launches Salesforce Backup: Offering Comprehensive, Automatic Cloud-to-Cloud Backup for Salesforce Data and Metadata
organization, greatly simplifying compliance and data governance workflows.Triple-Layer Data Protection: Backups are encrypted using AES 256-bit encryption and stored securely in the cloud, with robust safeguards and enterprise-grade security in place.Compliance - IDrive
More news about: IDrive Inc.
Dec 17, 2025, 09:07 ET Cerapedics Announces Publication in Spine of 24-Month ASPIRE Study Results of PearlMatrix™ P-15 Peptide Enhanced Bone Graft
differences between treatment groups with respect to ODI improvement, neurological deficits (motor and sensory), and serious device-related adverse events (AEs)."The ASPIRE study not only demonstrated higher fusion rates for PearlMatrix, as compared to local autograft in TLIF procedures, but it did so
More news about: Cerapedics Inc.
Dec 16, 2025, 16:01 ET Collective Mining Expands Ramp Zone by Drilling its Highest Grade Intercept Ever at Apollo: 24.80 Metres @ 29.42 g/t Gold Within 63.90 Metres @ 13.46 g/t Gold from 388.25 Metres
assay with gravimetric finish on a 50g sample (Au-GRA22). Copper and silver were assayed by inductively Coupled Plasma - Atomic Emission Spectroscopy (ICP-AES) and Mass Spectrometry (ICP-MS) following a 4-acid digestion. Samples were also analyzed for a suite of 48 elements with ME-MS61 plus mercury and a
More news about: Collective Mining Ltd.
Dec 16, 2025, 15:00 ET China's Tech Rising Star Zhongwei Sail Breaks Micro LED Barriers; First Solutions Set for Global Debut at AES in UAE
verification chip. Achieving critical performance breakthroughs, the company's inaugural solutions will make their international debut at the 19th AES Consumer Electronics Show in the UAE this December. Despite being established less than a year ago, ZW-Sail has demonstrated remarkable "China
More news about: ZW-sail
Dec 15, 2025, 11:30 ET PRIME AE Expands Transportation and Environmental Capabilities through Acquisition of Faller, Davis & Associates, Inc.
renowned for its expertise in transportation design, operations, planning, and environmental services. This strategic acquisition strengthens PRIME AE's presence across the Southeast and enhances our ability to deliver comprehensive infrastructure solutions to public-sector clients throughout Florida,
More news about: PRIME AE; Platform Holdings Capital
Dec 15, 2025, 05:00 ET Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
for intravenous IGF-1R antibodies. The treatment was well tolerated, with a favorable safety profile. No unique toxicities or Grade≥3 hearing-related AEs were observed.Chronic TED: At the 450 mg dose (n=33), MHB018A achieved a 76% proptosis response rate at Week 24, exceeding
More news about: Minghui Pharmaceutical
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
interleukin-17 (IL-17) inhibitor currently in clinical development.ASC50 was safe and well tolerated in the SAD study. All adverse events (AEs) were mild (Grade 1) and transient. No serious adverse events (SAEs) were reported. There was no discontinuation in the study. No hepatic safety signal
More news about: Ascletis Pharma Inc.
Dec 14, 2025, 17:00 ET PMET Announces Multiple New Lithium/Caesium Discoveries in 2025 Drilling at the Shaakichiuwaanaan Property
BC, where the samples were homogenized and subsequently analyzed for multi-element (including Li, Ta, and Cs) using sodium peroxide fusion with ICP-AES/MS finish (codes GE_ICP91A50 and GE_IMS91A50). Overlimits for Cs were completed at SGS Canada's laboratory in Lakefield, ON, by borate-fusion XRF (code
More news about: PMET Resources Inc.
Dec 11, 2025, 19:00 ET Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
period, there were no serious adverse events (SAEs) reported in the mazdutide groups, and no subjects discontinued treatment due to adverse events (AEs).there are currently no approved weight-loss medications specifically indicated for children and adolescents in China. A Phase
More news about: Innovent Biologics
Dec 11, 2025, 07:47 ET Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
or with lymph node metastasis. The toxicity of the Keynote-522 regimen is high, with 80% of patients experiencing grade 3 or higher treatment-related AEs, including treatment-related adverse events that lead to death in 0.5% of patients. About a Potential INT230-6 Approval Pathway in the Presurgical
More news about: Intensity Therapeutics Inc.
Dec 10, 2025, 13:07 ET NewSoftwares LLC Releases Folder Lock 10.1.13 for Windows and Launches First macOS Edition
smoother operation across the suite's tools.Folder Lock 10 continues to offer advanced capabilities including:256-bit (AES) on-the-fly encryption for instant protection without manual decryptionSecure cloud synchronization that encrypts files before they reach OneDrive,
More news about: NewSoftwares LLC
Dec 09, 2025, 07:30 ET Recordati Rare Diseases Announces Real-World Data on Long-Term Safety of ENJAYMO® (sutimlimab-jome) in Cold Agglutinin Disease and Cold Agglutinin Syndrome (CAD/CAS) at American Society of Hematology (ASH) Annual Meeting
(18.7) months, respectively. Sutimlimab is not approved in CAS.A total of 159 adverse events (AEs) were reported in 33 (52.4%) of the sutimlimab-treated patients. Six (9.5%) patients experienced AEs that the investigator considered related to sutimlimab. Of the 37 serious adverse events (SAEs) reported
More news about: Raliance Communications
Dec 08, 2025, 10:30 ET Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition
profile.AEs of grade 3 or higher occurred in 85% of patients in the LD arm and 90.2% of patients in the SD arm. Treatment discontinuation due to AEs occurred in 2.5% of patients in the LD arm versus 17.1% of patients in the SD arm.The most commonly reported treatment-emergent AEs were anemia
More news about: Taiho Oncology
Dec 08, 2025, 09:06 ET Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
and major mutation groups (SF3B1, TET2, DNMT3A, ASXL1, TP53).Favorable safety profile, with no treatment-related SAEs, no Grade ≥3 related AEs, and no evidence of treatment-emergent myelosuppression.These findings reinforce NEK7 inhibition as a promising strategy to address the
More news about: Halia Therapeutics
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
phase 3 study investigating adjunctive fenfluramine (FFA) in children and adults with CDKL5 deficiency disorder (CDD) at the American Epilepsy Society (AES) meeting in Atlanta, December 5-9, 2025.1 The trial met its primary endpoint and two of the three key secondary endpoints, demonstrating a
More news about: UCB
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
events (AEs) were grade 1 (mild) and grade 2 (moderate) in severity and mostly occurred during the dose titration period. There were no grade 3 (severe) or above GI AEs. In the ASC30 Phase II study, there were no any AEs of grade 3 (severe) or above and there were no drug related serious AEs (SAEs).The
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
https://www.multivu.com/ucb/9369551-en-presents-positive-results-from-gemz-phase-3-study-at-aes"UCB is proud to share these important results with the medical community at AES, especially given the significant unmet need in CDD. Families
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
https://www.multivu.com/ucb/9369551-en-presents-positive-results-from-gemz-phase-3-study-at-aes"UCB is proud to share these important results with the medical community at AES, especially given the significant unmet need in CDD. Families
More news about: UCB
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
treatment-emergent adverse events (AEs) and treatment discontinuation due to AEs were overall similar between arms. However, those receiving pirtobrutinib experienced lower rates of AE-related dose reductions, treatment discontinuation due to progressive disease, and certain cardiovascular AEs including hypertension
More news about: American Society of Hematology
Dec 06, 2025, 12:28 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1DEEs are a group of devastating,
More news about: H. Lundbeck A/S
Dec 06, 2025, 12:25 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1DEEs are a group of devastating,
More news about: H. Lundbeck A/S
Dec 05, 2025, 17:00 ET AES Announces Quarterly Dividend
www.aes.com by selecting "Investors" then "Stock Information" and then "Dividend History."About AESThe AES Corporation (NYSE: AES) is a Fortune 500 global energy company accelerating the future of energy. Together with our many stakeholders, we're improving lives
More news about: The AES Corporation
Dec 05, 2025, 09:00 ET Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) at the American Epilepsy Society (AES) 2025 Annual Meeting, being held December 5-9, 2025, in Atlanta, Georgia. Notable data include new results from the EpiCom trial, an ongoing
More news about: Jazz Pharmaceuticals plc
Dec 05, 2025, 09:00 ET NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
-- Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will participate in the American Epilepsy Society (AES) Annual Meeting December 5-9, 2025 in Atlanta. The Company will present a collection of eight posters focused on evaluation of diazepam nasal spray for
More news about: Neurelis, Inc.
Dec 04, 2025, 08:12 ET UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
placebo-controlled study. AES. 2025. Abstract number: 2.429.3 Gil-Nagel A, et al. Final Results From a Long-Term Open-Label Extension Study (Up to 4 Years): Tolerability of Fenfluramine and Global Functioning of Pediatric and Adult Patients With Dravet or Lennox-Gastaut Syndromes. AES. 2025. Abstract
More news about: UCB